GSK and Google invest 5 billion: to develop a new field of bioelectric therapy

GlaxoSmithKline (GSK) and Google believe. Today, GSK and Google's Verily announced the partnership to build Galvani Bioelectronics to open up a new field of bioelectric therapy. If successful, these chronic diseases will usher in bioelectric therapy for the first time.

GSK and Google invest 5 billion: to develop a new field of bioelectric therapy

â–²Luigi Galvani is a pioneer in the field of bioelectricity (Source: Wikipedia)

Human exploration of bioelectricity has been around for a long time. In 1780, Italian scientist Luigi Galvani discovered that when metal was used to contact the frog's sciatic nerve, the frog's legs contracted. This critical experiment laid the foundation for bioelectricity and paved the way to electrophysiology and neuroscience. These two university departments are precisely the key to bioelectric therapy. To commemorate Galvani's contribution, the new company was also named after his surname.

Although more than 200 years of development, bioelectric therapy is still an emerging field. GSK plans to implant small electrical devices in patients to alter the electrical signals in the human body. These signals can become irregular in many chronic diseases. Artificially implanted devices are expected to correct them.

GSK and Google invest 5 billion: to develop a new field of bioelectric therapy

â–² According to the plan, these micro-devices are only about the same size as a grain of rice (Source: GSK official website)

Since 2012, GSK has attempted to use this device to treat asthma, diabetes and arthritis, and to improve the patient's symptoms. In just four years, the potential of bioelectric therapy has emerged. Therefore, GSK and Google jointly invested 715 million US dollars (about 5 billion yuan), plans to verify its effectiveness as soon as possible, and bring it to patients.

GSK is very optimistic about the cooperation between the two companies. In the press release, GSK believes it can provide Galvani with world-class new drug development capabilities and a rich knowledge base on disease. At the same time, Verily brings the world's leading micro-device manufacturing process, data analysis and software development capabilities to the new company. The two sides plan to test the clinical feasibility of treating inflammation, metabolic diseases and endocrine diseases at an early stage, and develop related equipment.

GSK and Google invest 5 billion: to develop a new field of bioelectric therapy

â–² By adjusting the electrical signal dialogue between the brain and the organ, these small devices are expected to alleviate the symptoms of chronic diseases (Source: GSK official website)

“Many of the human body's activities are controlled by electrical signals between the nervous system and organs, and these signals may become dysfunctional in chronic diseases,” said Dr. Moncef Slaoui, Chairman of GSK Global Vaccines and Chairman of Galvani. “The vision of bioelectric therapy. Using the latest advances in biotechnology, interpreting the communication between these electrical signals, and using the micro-devices attached to the nerves to correct the wrong electrical signals. If it succeeds, it can bring a kind of medicine and vaccine. A new treatment plan."

“This is an ambitious collaboration,” said Dr. Brain Otis, Chief Technology Officer of Verily. “Bio-electricity is a medical field that is experiencing an outbreak. For success, a deep understanding of the disease and top-notch micro-device technology. It is indispensable."

PVC Gloves

pvc gloves,pvc vinyl gloves,vinyl gloves

HOLIK ASIA GROUP CO.LTD , https://www.holikasia.com